Abstract:Abstract Nonbiased mutational screening to identify essential genes and pathways in cancer is a powerful approach for understanding underlying biology as well as the identification of potential therapeutic targets. Epigenetic (EPI) and transcriptional factors (TF) play an important role in the change of phenotype and lineage plasticity from adenocarcinoma to castration resistant prostate cancer (CRPC), double negative (DN) or treatment-induced neuroendocrine prostate cancer (NEPC). When RB1 loss occurs in combination with TP53 alterations, stemness and lineage plasticity increase with one consequence being differentiation to a neuroendocrine (NE) lineage. Here, we are identifying and testing the functional role of epigenetic and transcription factors required for the viability of CRPC, DN and NEPC relative to a matrix of genotypic and phenotypic characteristics. We applied CRISPR-CAS9 dropout screens in prostate organoids and cell lines to identify gene/s associated with CRPC, DN and NEPC viability. We successfully CRISPR-engineered LNCaP clones of single (LNCaP-TP53-SKO, LNCaP-RB1-SKO) and double (LNCaP-TP53-RB1-DKO) gene knockouts, which were subsequently characterized for immuno-phenotype and transcriptome. Our dropout screens, targeting all TFs and EPIs, identified 117 TF and 40 EPI genes responsible for the viability of DN, NEPC and LNCaP models. We found known genes such as FOXA1 and ASCL1, as well as novel genes including PROX1 and KLF3, which were validated through guide RNA competition assays. Our results showed PROX1 is essential for cell viability in a DN organoid model, and its expression is associated with increased aggressiveness, indicating PROX1 has role in stemness/lineage plasticity in treatment resistant adenocarcinoma. RNA-seq analysis following overexpression of PROX1 in the LNCaP-TP53-RB1 null adenocarcinoma model, with and without enzalutamide, identified pathways enriched for cell proliferation, differentiation, neuronal development, and prostate gland development. In summary, our study has suggested an important role for PROX1 in the growth and differentiation of poorly differentiated prostate cancer, which may lead to the identification of potential therapeutic targets. Citation Format: Sonam Raj, Brian Capaldo, Joel Bowman, Margaret White, Xavier Moore, Berkley Gryder, Aian N. Alilin, David Takeda, Kathleen Kelly. Determining the role of PROX1 in prostate cancer neuroendocrine trans-differentiation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 554.

Supplementary Figures 1-6 from Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 As a Regulator of Docetaxel Resistance in Prostate Cancer Cells

Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 As a Regulator of Docetaxel Resistance in Prostate Cancer Cells

Targeting XPO6 Inhibits Prostate Cancer Progression and Enhances the Suppressive Efficacy of Docetaxel

AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

Single-Cell Proteomic and Transcriptomic Characterization of Drug-Resistant Prostate Cancer Cells Reveals Molecular Signatures Associated with Morphological Changes

Regulation of Docetaxel Chemosensitivity by NR2F6 in Breast Cancer

Single-cell Transcriptome Reveals the Heterogeneity of Malignant Ductal Cells and the Prognostic Value of REG4 and SPINK1 in Primary Pancreatic Ductal Adenocarcinoma

Down-regulation of UTP23 Promotes Paclitaxel Resistance and Predicts Poorer Prognosis in Ovarian Cancer.

AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification

Supplemental Fig. 1 from Notch Pathway Inhibition Using PF-03084014, a Γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer

Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells

Prostate cancer cell-derived exosomes ZNF667-AS1 reduces TGFBR1 mRNA stability to inhibit Treg expansion and DTX resistance by binding to U2AF1

A comprehensive gene expression profile analysis of prostate cancer cells resistant to paclitaxel and the potent target to reverse resistance

Txr1: A Transcriptional Regulator Of Thrombospondin-1 That Modulates Cellular Sensitivity To Taxanes

RBPJ Contributes to Acquired Docetaxel Resistance in Prostate Cancer Cells

Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells.

INPP4B Reverses Docetaxel Resistance and Epithelial-to-mesenchymal Transition Via the PI3K/Akt Signaling Pathway in Prostate Cancer.

Suppl. Figure 2 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy

Abstract 554: Determining the role of PROX1 in prostate cancer neuroendocrine trans-differentiation